Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A study using botulinum toxin type A as headache prophylaxis for migraine patients with frequent headaches

Trial Profile

A study using botulinum toxin type A as headache prophylaxis for migraine patients with frequent headaches

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jul 2018

At a glance

  • Drugs Botulinum-Toxin-A (Primary)
  • Indications Migraine
  • Focus Registrational; Therapeutic Use
  • Acronyms PREEMPT-2
  • Sponsors Allergan
  • Most Recent Events

    • 01 Jul 2018 Results of the pooled analysis of PREEMPT 1 and 2 (n=1384) assessing the time of onset of the effect of onabotulinumtoxinA on reduction of headache days and migraine days, presented at the 60th Annual Scientific Meeting of the American Headache Society
    • 10 Jun 2016 Results of pooled analysis of two phase III trials ( PREEEMPT-I and PREEEMPT-II trials) published in the Cephalalgia
    • 31 Aug 2012 Results from a pooled analysis of the PREEMPT programme presented at the 14th World Congress on Pain.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top